Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Assets Average (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Assets Average for 12 consecutive years, with $420.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average rose 17.18% to $420.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $420.7 million, a 17.18% increase, with the full-year FY2020 number at $438.9 million, down 9.41% from a year prior.
  • Assets Average was $420.7 million for Q3 2025 at Theravance Biopharma, up from $384.8 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $685.4 million in Q4 2022 to a low of $348.9 million in Q1 2025.
  • A 5-year average of $432.3 million and a median of $402.2 million in 2021 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: soared 51.09% in 2023, then crashed 31.51% in 2024.
  • Theravance Biopharma's Assets Average stood at $416.2 million in 2021, then surged by 64.7% to $685.4 million in 2022, then tumbled by 37.25% to $430.1 million in 2023, then dropped by 17.43% to $355.1 million in 2024, then grew by 18.48% to $420.7 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Assets Average are $420.7 million (Q3 2025), $384.8 million (Q2 2025), and $348.9 million (Q1 2025).